Devonian Health Group (CVE:GSD) Trading Up 11.5% – Time to Buy?

Shares of Devonian Health Group Inc. (CVE:GSD) were up 11.5% on Friday . The stock traded as high as C$11.15 and last traded at C$11.15. Approximately 2,600 shares were traded during mid-day trading, an increase of 120% from the average daily volume of 1,184 shares. The stock had previously closed at C$10.00.

Devonian Health Group Stock Up 11.5%

The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The company has a 50-day simple moving average of C$11.80 and a two-hundred day simple moving average of C$11.70. The stock has a market cap of C$31.01 million, a P/E ratio of -3.21 and a beta of 1.09.

About Devonian Health Group

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.